Virax Biolabs Group Limited (VRAX) Financial Ratios
6 years of historical data (2020–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.12
↓-80% vs avg
5yr avg: 0.59
30Y Low0.3·High0.8
ROE
↑
-114.4%
↓+3% vs avg
5yr avg: -117.3%
30Y Low-142%·High-96%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Virax Biolabs Group Limited currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $4M | $1M | $7M | — | — | — |
| Enterprise Value | $-2300443 | $-313891 | $-1926345 | $-1814304 | — | — | — |
| P/E Ratio → | -0.11 | — | — | — | — | — | — |
| P/S Ratio | 245.06 | 558.85 | 9.20 | 863.45 | — | — | — |
| P/B Ratio | 0.12 | 0.65 | 0.28 | 0.83 | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -49.58 | -12.32 | -211.93 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Profitability
Margins and return-on-capital ratios measuring operating efficiency
Virax Biolabs Group Limited earns an operating margin of -97344.8%. Operating margins have compressed from -66963.7% to -97344.8% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -114.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | -838.2% | -838.2% | 32.3% | -15.9% | — | -7.6% | 45.8% |
| Operating Margin | -97344.8% | -97344.8% | -4153.3% | -66963.7% | — | -520.5% | -652.1% |
| Net Profit Margin | -95739.2% | -95739.2% | -4304.8% | -63748.3% | — | -525.8% | -802.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -114.4% | -114.4% | -95.9% | -141.6% | — | — | — |
| ROA | -101.8% | -101.8% | -88.0% | -110.7% | -2392.9% | -1115.4% | -3543.4% |
| ROIC | -273.2% | -273.2% | -662.2% | — | — | — | — |
| ROCE | -111.4% | -111.4% | -91.4% | -148.8% | — | — | — |
Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $4M exceeds total debt of $377004, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.04 | 0.02 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.71 | -0.65 | -1.03 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -105.93 | -105.93 | -241.70 | -370.62 | -112.30 | -22.50 | -7.18 |
Net cash position: cash ($4M) exceeds total debt ($377004)
Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Virax Biolabs Group Limited's current ratio of 7.27x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 10.61x to 7.27x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 7.27 | 7.27 | 25.94 | 10.61 | 0.04 | 0.05 | 0.02 |
| Quick Ratio | 7.13 | 7.13 | 25.58 | 10.58 | 0.02 | 0.02 | 0.02 |
| Cash Ratio | 6.28 | 6.28 | 21.26 | 10.30 | 0.02 | 0.02 | 0.02 |
| Asset Turnover | — | 0.00 | 0.03 | 0.00 | — | 1.32 | 4.42 |
| Inventory Turnover | 0.63 | 0.63 | 1.75 | 0.41 | — | 6.32 | — |
| Days Sales Outstanding | — | 1767.29 | 508.33 | — | — | 2.74 | — |
Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Virax Biolabs Group Limited does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $3M | $2M | $1M | $1M | $1M | $1M |
Peer Comparison
Compare VRAX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 VRAXYou | $2M | -0.1 | — | — | -838.2% | -97344.8% | -114.4% | -273.2% | — |
 CAI | $33B | -6.2 | 718.4 | 496.4 | — | 5.6% | -93.2% | — | 0.0 |
 VCYT | $3B | 44.2 | 44.2 | 22.7 | 70.1% | 11.2% | 5.3% | 4.4% | 0.7 |
 ADPT | $3B | -15.2 | — | — | 59.7% | -90.8% | -62.5% | -41.6% | — |
 NAUT | $331M | -5.6 | — | — | — | — | -32.3% | — | — |
 CDIO | $141M | -0.6 | — | — | 100.0% | -23977.9% | -134.0% | -222.7% | — |
 SEER | $103M | -1.3 | — | — | 49.0% | -717.7% | -23.9% | -21.3% | — |
 IMDX | $95M | -1.2 | — | — | 39.3% | -3245.1% | -1480.7% | — | — |
 ASBP | $63M | -5.1 | — | — | — | — | — | — | — |
 YDES | $35M | -15.1 | — | — | 30.4% | -286.5% | -42.7% | -63.3% | — |
 AIMD | $7M | -1.0 | — | — | -153.7% | -66772.2% | -74.4% | -39.8% | — |
| Healthcare Median | — | 23.2 | 14.9 | 19.0 | 65.8% | -6.4% | -36.7% | -13.6% | 3.0 |
Peers based on L4 peer group classification. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
See VRAX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VRAX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare VRAX vs CAI
See how VRAX stacks up against sector leader Caris Life Sciences, Inc..
Start ComparisonFrequently Asked Questions
What is Virax Biolabs Group Limited's P/E ratio?
Virax Biolabs Group Limited's current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is Virax Biolabs Group Limited's ROE?
Virax Biolabs Group Limited's return on equity (ROE) is -114.4%. The historical average is -117.3%.
Is VRAX stock overvalued?
Based on historical data, Virax Biolabs Group Limited is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Virax Biolabs Group Limited's profit margins?
Virax Biolabs Group Limited has -838.2% gross margin and -97344.8% operating margin.